This ‘weak pill’ can be a progress for cancer that has only a 10% survival rate

They are getting diving.

A small number of Canadian cancer patients are testing a pill containing healthy human bacteria to see that they can extend their lives.

“Pancreas cancer has a poor survival rate of approximately 10% over five years,” Oncologist Medical Dr. Said John Leneehan. “Through this study, we aim to provide a new, innovative treatment for patients.”

Cancerous tumors are believed to have a collection of bacteria, viruses and fungi that help the disease protected from treatments such as chemotherapy.

Fecal transplants, which are usually made of collooscopy, help restore healthy intestinal bacteria.

Early studies suggest that fecal transplants delivered your oral capsule known as the CND101 can change the microbial composition of the tumors and make the body more capable of fighting advanced pancreatic cancer.

Lenehan’s team is launching a two-year clinical test of Phase 1 that includes 20 patients at the Vespeten Family Cancer Center at the London Health Science Center.

Scat from healthy donors is processed in the laboratory to generate tasteless, odorless pills. Hope is to improve patients’ healthy microorganisms to boost their immune response and potentially make chemotherapy more effective.

“We will study how the intestinal bacteria of patients with pancreatic cancer change after treatment with fecal transplants using capsules and how it affects their immune system,” the same Malpaj, a scientist at the London Health Science Center (LHSCRI), said.

“Our goal is to determine whether a successful shift in the intestinal microbioma is associated with a better response to chemotherapy.”

“Weak pills” are not new. The US Food and Drug Administration (FDA) approved Vowst, the first form of the fecal transplant therapy pill in 2023.

LND101 pills have already shown promises in advanced melanoma, lung cancer and renal cell carcinoma, LHSCRI scholars said, and they hope to achieve success similar to late pancreatic cancer.

Pancreas cancer is often detected in advanced stages because it does not use the use of symptoms until it spreads to organs beyond the pancreas, limiting treatment approaches.

About 67,400 Americans will be diagnosed with pancreatic cancer this year and nearly 52,000 will die from the disease, the American Cancer Association project.

The LHSCRI team is looking for weak donors. If you are interested, the email Liesl de Silva in Liesl.Desilva@sjhc.London.on.ca or Call (519) 646-6100, EKST. 65739.